LY307161 SR, a long-acting GLP-1 analog, improved glycemic control in patients with type 2 diabetes

被引：0
|
作者：
Trautmann, M
Chen, CF
Chappell, J
Dananberg, J
Patterson, B
Klausmann, G
Kapitza, C
机构：
来源：
DIABETES | 2003年 / 52卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：A136 / A136
页数：1
相关论文
共 50 条
  • [1] LY307161 SR, a long-acting GLP-1 analog, improved glycemic control in patients with Type 2 diabetes.
    Trautmann, ME
    Chen, CF
    Chappell, JC
    Dananberg, J
    Patterson, B
    Klausmann, G
    Kapitza, C
    DIABETOLOGIA, 2003, 46 : A63 - A63
  • [2] Daily administration of LY307161 SR (GLP-1 analog) normalizes blood glucose in Type 2 diabetes
    Kapitza, C
    Trautmann, ME
    Heise, T
    Heinemann, L
    Patterson, B
    DIABETES, 2002, 51 : A84 - A84
  • [3] LY307161 SR, a sustained release formulation of a GLP-1 analog, is suitable for once daily administration in patients with Type 2 diabetes
    Trautmann, ME
    Kapitza, C
    Mace, KF
    Patterson, B
    Hompesch, M
    Heise, T
    DIABETES, 2002, 51 : A135 - A135
  • [4] LY307161 SR: Extending the time action of GLP-1
    Myers, S
    Cox, A
    Irwin, L
    Compton, J
    Mace, KF
    DIABETES, 2002, 51 : A342 - A342
  • [5] The Pharmacokineties (PK) and Pharmacodynamics (PD) of LY307161 SR, a sustained release formulation of a GLP-1 analog, administered subcutaneously to patients with Type 2 diabetes
    Patterson, BE
    Trautmann, ME
    Mace, KF
    Ernest, CS
    DIABETOLOGIA, 2002, 45 : A43 - A43
  • [6] The GLP-1 analogue, LY307161, potently lowers post prandial blood glucose in subjects with type 2 diabetes.
    Pascoe, S
    Payne, C
    Trautmann, M
    DIABETOLOGIA, 2000, 43 : A31 - A31
  • [7] Glycemic control and long-acting insulin analog utilization in patients with type 2 diabetes
    Edith M. Heintjes
    Trine L. Thomsen
    Fernie J. A. Penning-van Beest
    Torsten E. Christensen
    Ron M. C. Herings
    Advances in Therapy, 2010, 27 : 211 - 222
  • [8] Glycemic Control and Long-Acting Insulin Analog Utilization in Patients with Type 2 Diabetes
    Heintjes, Edith M.
    Thomsen, Trine L.
    Penning-van Beest, Fernie J. A.
    Christensen, Torsten E.
    Herings, Ron M. C.
    ADVANCES IN THERAPY, 2010, 27 (04) : 211 - 222
  • [9] Once daily administration of LY307161 SR, a sustained release formulation of a Glp-1 Analogue, substantially reduces fasting and daytime glucose levels in patients with Type 2 diabetes
    Trautmann, ME
    Kapitza, C
    Hompesch, M
    Heise, T
    Mace, KF
    Patterson, B
    DIABETOLOGIA, 2002, 45 : A43 - A43
  • [10] The effect of NN2211, a long-acting GLP-1 derivative, on glycemic control and body weight in obese patients with Type 2 diabetes
    Saad, M
    An, B
    Santiago, O
    DIABETOLOGIA, 2002, 45 : A44 - A44
12345